The clinical significance of heterogeneity in asthma

The clinical significance of ventilation heterogeneity in asthma, before and after 3 months of inhaled corticosteroid treatment

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000317695

Acronym

02AU02-Bron trial

Enrollment

Registered

2005-09-06

Start date

2003-06-27

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Asthmatics were assigned to either Respocort or QVAR treatment for the duration of 3 months.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Doctor-diagnosed asthma, with symptoms in the last 12 months.

Exclusion criteria

Current smoking (in the last 6 months)* > 10 pack year history of smoking* Any other lung disease* Oral prednisone use in the last 4 weeks* Respiratory tract infection in the last 4 weeks.

Outcome results